about
Integrated multimodal genetic testing of Ewing sarcoma--a single-institution experience.Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.Multimodality Treatment of Pediatric Esthesioneuroblastoma.Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.Changes mimicking new leptomeningeal disease after intensity-modulated radiotherapy for medulloblastoma.Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma.Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.Medulloblastoma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors in a child: case report.A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children.A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicityElevated expression of CXC chemokines in pediatric osteosarcoma patientsA single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir.Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcomaInfantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy.Retinoblastoma: review of current management.Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy.Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous systemCommon variants in ACYP2 influence susceptibility to cisplatin-induced hearing lossClinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.Retinoblastoma: from bench to bedside.Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation.A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997.Residual intraretinal retinoblastoma after chemoreduction failureIs CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001)Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain TumorsRadiation-induced malignant gliomas: is there a role for reirradiation?Anaplastic ganglioglioma arising from a Lhermitte-Duclos-like lesion. Case report.A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET.Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study.Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.Correlation of Insurance, Race, and Ethnicity with Pathologic Risk in a Controlled Retinoblastoma Cohort: A Children's Oncology Group Study.
P50
Q27852296-0B0B31E9-4FF4-4C87-8423-AF4CBB75E32CQ27853187-2EB0AAE7-9C77-4819-9C03-84EBAEC8A9A7Q30353927-FDC2CD97-8FF4-4384-9895-DC714DC26329Q30578179-8149B0B8-95FE-4D2B-B996-A78DBA2EE7B4Q31155595-3CE0C8BD-5096-41CB-8AAC-183D8C52592CQ33242191-BC4E1F84-3561-4AB0-B03F-A1567B085402Q33363847-102DE47E-E448-4094-B62C-706B6384A699Q33375910-2C649077-03A8-4018-96D0-147B2C680320Q33418912-0628A54A-6370-415A-87BF-C9D5545A3526Q33528073-42EE16F9-9872-41EC-B6A2-920BB26C7A2EQ33616598-F1071389-1793-4BB0-9378-450AD66F28D5Q34132933-FED390A8-6BED-414A-BD03-C28D892C9657Q34325212-B6D22659-7F01-4535-A169-38DD7457CA73Q34380220-4086CA6B-DC7C-433F-B162-7C005B45148CQ34480521-05FCA577-5BF1-4A0F-8414-4CE979F34F01Q34562176-0216DEF5-5214-48C8-8B27-60E22AD36BD7Q34593395-7BDBFFA9-0DE6-4456-B6A2-7CE168FD101BQ34606145-ACBFB541-6ED4-4B2A-96E6-CC48D818D1CCQ34707046-6FBC9040-F93D-4A28-9D33-2B24C73BB8A2Q35069288-E6B58321-8404-48CF-ACAD-D4C8D9A2128FQ35083170-76D1A36E-0BEC-40D7-83FA-4F8F88B2326EQ35172741-54E4EDEB-EE1A-468F-A9DD-0C291CE6106AQ35670006-B83D64B5-3881-4CBC-83D3-B35D002BA843Q35677136-DDE037B5-C576-48BE-B8A5-1887A1428F36Q35747427-1818107C-8F52-42E8-9F38-7FED6C373DB5Q35815306-90D8BEB5-E213-422E-8374-9B387C2EF0B1Q35976346-369E60E2-8F0C-4301-8D5C-99820963B579Q36157681-0C495845-DE86-4E53-8295-292D927A4586Q36181306-BBA538F3-F292-4FEF-BC76-0176A57B8F9EQ36485382-D89B2A63-5B66-47E9-A9E7-6E0FF2D0747EQ36825081-8942CA95-F3EF-432E-986F-C10BBA05895DQ36865982-F4707B76-54D9-4F91-887D-5F03156204CBQ36914415-A82F8C6A-C3C1-4A61-805C-CF92824DE8A0Q37080650-04439698-252D-4BBF-BDCF-886EC6382EF7Q37155772-323A5DC1-B925-49B3-A5D9-560123FFADC5Q37284226-993D536D-A21D-4F1A-81F5-E4A5F25BDBB2Q37284259-4B56C58E-19D7-400D-97AE-42D744B84964Q37374218-4ECEC97F-6581-4157-AA99-D2BBF0F2864EQ37375947-189BC09A-3B49-4E46-8700-C0BAA36A0F91Q37509722-B36F1496-2A7D-40BA-9233-A4FF94288E86
P50
description
onderzoeker
@nl
name
Murali Chintagumpala
@ast
Murali Chintagumpala
@en
Murali Chintagumpala
@es
Murali Chintagumpala
@sl
type
label
Murali Chintagumpala
@ast
Murali Chintagumpala
@en
Murali Chintagumpala
@es
Murali Chintagumpala
@sl
prefLabel
Murali Chintagumpala
@ast
Murali Chintagumpala
@en
Murali Chintagumpala
@es
Murali Chintagumpala
@sl